Abstract:Background and aims: Peroxisome proliferator-activated receptor alpha (PPARa) regulates expression of multiple genes involving lipid metabolism, bile acids (BA) homeostasis, and shows protective effects against inflammation and apoptosis.Progressive diseases such as primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) result in intrahepatic retention of toxic BA that may lead to liver dysfunction and failure.Small non-coding RNA molecules (miRNAs) regulate gene expression, and miR-155 was associated with silencing of PPARa.Since PPARa activation decreases inflammation and fibrosis we evaluated PPARa and miR-155 expressions in cholestatic livers.We have also analyzed the regulatory effect of miR-155 on PPARa expression in vitro.Method: Liver samples were taken from biopsies at early stages (F1-F2) of PBC (n = 12) or from explanted livers in patients with cirrhotic PBC (n = 11) and PSC (n = 17).The functional role of miR-155 was characterized in vitro in hepatocytes (HepG2) and primary cholangiocytes (NHC) where overexpression of miR-155 was induced by mirVana miRNA Mimic.miR-155 expression levels were evaluated after treatment with lipopolysaccharide (LPS), glycodeoxycholic acid (GCDCA), lithocholic acid (LCA) or ursodeoxycholic acid (UDCA).Results: When compared to controls hepatic PPARa mRNA and protein levels were reduced in cirrhotic PBC (both 50% reduction, P = 0.01), but not in PSC livers.In PBC livers this phenomenon was accompanied with induction of miR-155 (3.7-fold increase, P = 0.004 vs. control).Experimental overexpression of miR-155 in HepG2 led to the inhibition of PPARa (50% reduction, P = 0.02).LPS stimulated miR-155 expression in HepG2 (over 40-fold increase, p = 0.009), whereas the treatment with GCDCA or LCA enhanced the expression of miR-155 in NHC (2-fold p < 0.05, or 2.4 fold p < 0.05, respectively).UDCA suppressed the basal expression of miR-155 in NHC (20% reduction, p = 0.02 vs. control) as well as the LPS-induced miR-155 in HepG2 ( p = 0.009 vs LPS). Conclusion:We showed that PPARa is substantially reduced in PBC livers, and the observed concomitant overexpression of miR-155 induced either by inflammation or bile acids may be accountable for this suppression.Inhibition of miR-155 may be a potential novel therapeutic target in PBC.

PPARα activation protects against cholestatic liver injury

Differential gene expression in mouse primary hepatocytes exposed to the peroxisome proliferator-activated receptor α agonists

Peroxisomal Fitness: A Potential Protective Mechanism of Fenofibrate against High Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Mice

Fenofibrate Downregulates NF-κB Signaling to Inhibit Pro-inflammatory Cytokine Secretion in Human THP-1 Macrophages and During Primary Biliary Cholangitis

Fenofibrate Attenuates Hepatic Fibrosis by PPAR-Α and TGF-β1/Smad Signaling Pathway Via Modulating Autophagy and Oxidative Stress

Metabolomics Reveals That PPARα Activation Protects Against Lithocholic Acid-Induced Liver Injury

Disruption of peroxisome proliferator-activated receptor α in hepatocytes protects against acetaminophen-induced liver injury by activating the IL-6/STAT3 pathway

Expression and Antioxidant Function of Liver Fatty Acid Binding Protein in Normal and Bile-Duct Ligated Rats

Cholangiocytes-Specific Deletion of Sphingosine-1-phospholipid Receptor 1 Attenuate Cholestasis Induced Liver Injury and Fibrosis

Pirfenidone ameliorates ANIT-induced cholestatic liver injury via modulation of FXR, NF-кB/TNF-α, and Wnt/GSK-3β/β-catenin signaling pathways

Peroxisome Proliferator-Activated Receptors Regulate Hepatic Immunity and Assist in the Treatment of Primary Biliary Cholangitis

Peroxisome Proliferator-Activated Receptor Alpha Acts As A Mediator of Endoplasmic Reticulum Stress-Induced Hepatocyte Apoptosis in Acute Liver Failure

The role of peroxisome proliferator-activated receptors in the regulation of bile acid metabolism

Paeoniflorin Protects against ANIT-Induced Cholestatic Liver Injury in Rats via the Activation of SIRT1-FXR Signaling Pathway

PPARα/γ Agonists and Antagonists Differently Affect Hepatic Lipid Metabolism, Oxidative Stress and Inflammatory Cytokine Production in Steatohepatitic Rats

Activation of pregnane X receptor protects against cholestatic liver injury by inhibiting hepatocyte pyroptosis

PPAR-Mediated Bile Acid Glucuronidation: Therapeutic Targets for the Treatment of Cholestatic Liver Diseases

Serum Metabolomic Profiling in a Rat Model Reveals Protective Function of Paeoniflorin Against ANIT Induced Cholestasis.

Pterostilbene Alleviates Cholestasis by Promoting SIRT1 Activity in Hepatocytes and Macrophages

Metabolomic Analysis Reveals the Therapeutic Effects of MBT1805, a Novel Pan-Peroxisome Proliferator-Activated Receptor Agonist, on Α-Naphthylisothiocyanate-induced Cholestasis in Mice

The Peroxisome Proliferator-activated Receptor Α (pparα) Regulates Bile Acid Biosynthesis*